FTH1P8 induces and transmits docetaxel resistance by inhibiting ferroptosis in prostate cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies FTH1P8 as a key driver of docetaxel resistance in prostate cancer by inhibiting ferroptosis. Targeting FTH1P8 with novel nanoliposomes offers a promising therapeutic strategy for overcoming treatment resistance.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- Docetaxel resistance is a major obstacle in prostate cancer treatment.
- Ferroptosis, a regulated form of cell death, is linked to docetaxel resistance.
- Identifying novel biomarkers and therapeutic targets is crucial for improving patient outcomes.
Purpose Of The Study
- To investigate the role of FTH1P8 in the development of docetaxel resistance in prostate cancer.
- To explore the molecular mechanisms underlying FTH1P8-mediated ferroptosis inhibition.
- To evaluate the therapeutic potential of targeting FTH1P8 in docetaxel-resistant prostate cancer.
Main Methods
- Comparative analysis of FTH1P8 expression in docetaxel-sensitive and resistant prostate cancer cells.
- Investigation of ferroptosis markers (Fe2+, lipid ROS, MDA, GSH, mitochondrial damage) upon FTH1P8 modulation.
- Correlation analysis of FTH1P8 and FTH1 expression using TCGA database.
- Molecular studies on FTH1P8 regulation by miR-1252-5p and its interaction with FTH1.
- Exosome-mediated transfer of docetaxel resistance via FTH1P8.
- Development and in vitro evaluation of docetaxel-siRNA targeting FTH1P8-nanoliposomes (DOC-siFTH1P8-LIP).
Main Results
- Docetaxel-resistant prostate cancer cells exhibit significantly higher FTH1P8 expression than sensitive cells.
- Downregulation of FTH1P8 restored sensitivity to docetaxel by promoting ferroptosis.
- Upregulation of FTH1P8 conferred docetaxel resistance and suppressed ferroptosis.
- FTH1P8 expression is positively correlated with FTH1 and regulated by miR-1252-5p.
- FTH1P8 promotes docetaxel resistance spread through exosomes.
- DOC-siFTH1P8-LIP effectively inhibited docetaxel resistance in vitro.
Conclusions
- FTH1P8 serves as a potential biomarker and therapeutic target for overcoming docetaxel resistance in prostate cancer.
- Modulating FTH1P8 levels can restore ferroptosis and re-sensitize cancer cells to docetaxel.
- DOC-siFTH1P8-LIP represents a promising novel therapeutic strategy for docetaxel-resistant prostate cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...